Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Birgit Engesæter"'
Publikováno v:
Norsk Epidemiologi, Vol 30, Iss 1-2 (2022)
An organised screening programme for cervical cancer (CervicalScreen Norway) was implemented in Norway in 1995. The overall aim of the programme is to reduce the incidence and mortality of cervical cancer, and the screening coverage should exceed 80%
Externí odkaz:
https://doaj.org/article/bbcd0eeac5824ff190213a3036fe2c88
Autor:
Irene Tveiterås Øvestad, Birgit Engesæter, Mari Kyllesø Halle, Saleha Akbari, Beatrix Bicskei, Morten Lapin, Marie Austdal, Emiel A. M. Janssen, Camilla Krakstad, Melinda Lillesand, Marit Nordhus, Ane Cecilie Munk, Einar G. Gudlaugsson
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 1, p 373 (2021)
Implementation of high-risk human papilloma virus (HPV) screening and the increasing proportion of HPV vaccinated women in the screening program will reduce the percentage of HPV positive women with oncogenic potential. In search of more specific mar
Externí odkaz:
https://doaj.org/article/dfc7af310fef480c927fc548096075c1
Autor:
Mari K. Halle, Ane Cecilie Munk, Birgit Engesæter, Saleha Akbari, Astri Frafjord, Erling A. Hoivik, David Forsse, Kristine E. Fasmer, Kathrine Woie, Ingfrid S. Haldorsen, Bjørn I. Bertelsen, Emiel A. M. Janssen, Einar Gudslaugsson, Camilla Krakstad, Irene T. Øvestad
Publikováno v:
Cancers, Vol 13, Iss 22, p 5737 (2021)
The purpose of this study was to establish a gene signature that may predict CIN3 regression and that may aid in selecting patients who may safely refrain from conization. Oncomine mRNA data including 398 immune-related genes from 21 lesions with con
Externí odkaz:
https://doaj.org/article/9a9dd981aa1545cda7b41aae1d03ee74
Autor:
Birgit Engesæter, Bianca van Diermen Hidle, Mona Hansen, Pia Moltu, Kjersti Mangseth Staby, Siri Borchgrevink-Persen, Olav K. Vintermyr, Stefan Lönnberg, Mari Nygård, Emiel A. M. Janssen, Philip E. Castle, Irene Kraus Christiansen
Publikováno v:
BMC Infectious Diseases, Vol 16, Iss 1, Pp 1-8 (2016)
Abstract Background Human papillomavirus (HPV) testing as primary screening for cervical cancer is currently being implemented in Norway in a randomized controlled fashion, involving three laboratories. As part of the quality assurance programme of t
Externí odkaz:
https://doaj.org/article/78758775caa04652966a7fe80862053e
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e45492 (2012)
Mapatumumab and lexatumumab (targeting death receptor 4 (DR4) and 5 (DR5), respectively) are agonistic TRAIL receptor antibodies that induce apoptosis in a wide range of cancer cells. The potency of mapatumumab and lexatumumab was assessed in mono th
Externí odkaz:
https://doaj.org/article/dfb613686fb049ada56685e0a3ea6c01
Autor:
Mari Nygård, Birgit Engesæter, Philip E. Castle, Jannicke Mohr Berland, Maj Liv Eide, Ole Erik Iversen, Christine Monceyron Jonassen, Irene Kraus Christiansen, Olav Karsten Vintermyr, Ameli Tropé
Publikováno v:
Cancer Epidemiology, Biomarkers and Prevention
Background: Cervical cancer screening programs are facing a programmatic shift where screening protocol based on human papillomavirus testing (HPV-Screening protocol) is replacing the liquid-based cytology (LBC-Screening protocol). For safe technolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c953fd3858ac61811d3a4660b37a3d7
https://hdl.handle.net/11250/3022883
https://hdl.handle.net/11250/3022883
Autor:
Emiel A. M. Janssen, Ingfrid S. Haldorsen, Bjørn I. Bertelsen, Saleha Akbari, Einar Gudslaugsson, Ane Cecilie Munk, Mari K. Halle, Camilla Krakstad, David Forsse, Kathrine Woie, Erling A. Hoivik, Birgit Engesæter, Irene T Øvestad, Kristine Eldevik Fasmer, Astri Frafjord
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5737, p 5737 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5737, p 5737 (2021)
Volume 13
Issue 22
The purpose of this study was to establish a gene signature that may predict CIN3 regression and that may aid in selecting patients who may safely refrain from conization. Oncomine mRNA data including 398 immune-related genes from 21 lesions with con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b2e99a344e436466b48f8852598647
https://hdl.handle.net/11250/2834091
https://hdl.handle.net/11250/2834091
Autor:
Gry Baadstrand Skare, Philip E. Castle, Ameli Tropé, Dana Hashim, Tone Bjørge, Birgit Engesæter, Mari Nygård
Publikováno v:
British Journal of Cancer
Background HPV16/18 detection may improve cervical cancer risk stratification and better guide which HPV-positive women warrant immediate colposcopy/biopsy. We estimated risks of cervical precancer and cancer by HPV genotype and cytology during the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579b6f65c01213539b0934e5cd4d3fe1
https://hdl.handle.net/11250/2740686
https://hdl.handle.net/11250/2740686
Autor:
Gunhild Mari Mælandsmo, Michael G. Rosenblum, Lina Prasmickaite, Pål Kristian Selbo, Ellen Skarpen, Soldano Ferrone, J. Kaur, A. Høgset, M. S. Eng, Birgit Engesæter, Kristian Berg, Anette Weyergang
Publikováno v:
Photochem Photobiol Sci
Triple-negative breast cancer (TNBC) and malignant melanoma are highly aggressive cancers that widely express the cell surface chondroitin sulfate proteoglycan 4 (CSPG4/NG2). CSPG4 plays an important role in tumor cell growth and survival and promote
Autor:
Giske Ursin, Kåre Moen, Bo T. Hansen, Ameli Tropé, Dana Hashim, Birgit Engesæter, Elisabete Weiderpass, Nathalie C. Støer, Trude Andreassen
Publikováno v:
International Journal of Cancer
From 2015, Norway has implemented high‐risk human papilloma virus (hrHPV) testing in primary screening for cervical cancer. Women aged 34–69 years, living in four counties, have been pseudo‐randomly assigned (1:1 randomization) to either hrHPV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f282e56200bb1fcc46c4f1e563ecc96
https://hdl.handle.net/10037/17750
https://hdl.handle.net/10037/17750